A detailed history of Casdin Capital, LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 350,000 shares of GH stock, worth $10.9 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares
350,000
Previous 100,000 250.0%
Holding current value
$10.9 Million
Previous $2.89 Million 177.87%
% of portfolio
0.62%
Previous 0.25%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.3 - $36.29 $5.58 Million - $9.07 Million
250,000 Added 250.0%
350,000 $8.03 Million
Q2 2024

Aug 14, 2024

BUY
$16.07 - $31.84 $1.61 Million - $3.18 Million
100,000 New
100,000 $2.89 Million
Q2 2022

Aug 15, 2022

SELL
$28.82 - $77.35 $4.25 Million - $11.4 Million
-147,500 Reduced 35.12%
272,500 $11 Million
Q1 2022

May 16, 2022

SELL
$48.25 - $100.49 $17.9 Million - $37.2 Million
-370,000 Reduced 46.84%
420,000 $27.8 Million
Q4 2021

Feb 14, 2022

BUY
$88.71 - $120.43 $70.1 Million - $95.1 Million
790,000 New
790,000 $79 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.18B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Casdin Capital, LLC Portfolio

Follow Casdin Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.